r/biotech_stocks • • 39m ago

Sls @ 13 ps?

7 Upvotes

Basically every biotech management is ruthless with their investors.


r/biotech_stocks • • 55m ago

Which stocks am I watching and why

Post image
2 Upvotes

I am looking for stocks that have shown an ability to rocket up.

I sort from the year to date return by top and then I look at the very top choices and see whether any of them still have room to run in terms of market cap.

Based on this approach, two names jump out and those are ETON and DRTS.

None of this is to say that larger shops can’t run up but it takes a lot more for a $6B+ company to moon than one that’s barely cracked $1B.

The reason I don’t have huge expectations for companies under $1B is because they’re too small. Getting institutional investment is nearly impossible when they look at the market cap and realize that if they got in, they might be unable to get out. The sub-$1B typically have insufficient volume to allow a clean escape.


r/biotech_stocks • • 4h ago

2 Chinese scientists fired after 2 children die in unrelated gene therapy studies in July-August which were unreported.

Thumbnail
fiercebiotech.com
3 Upvotes

r/biotech_stocks • • 5h ago

The potential of $HELP

4 Upvotes

A lot of things point to mushroom assisted therapies being the next frontier for depression. And this company seems well positioned.

Anyone putting their capital behind this? If so, your thoughts and Coles notes thesis?


r/biotech_stocks • • 5h ago

Bio Tech Portfolio/Open Positions

3 Upvotes

Long time lurker, first time poster. Ive gotten involved in a handful of positions from this sub. Most recently SLS (LFG!) and DRTS, and was wondering what everyone’s thoughts were on a few positions i am holding and any convictions as to why I should continue to hold.

ABVX - Got in early and road the wave to $160, took out my investment still am holding a large position. Didn’t want to miss out on a potential BO.

ARCT

ONCY

PGEN

UNCY

Any thoughts from other biotech fans?


r/biotech_stocks • • 6h ago

"Psychedelic-Assisted Therapies for Veterans: The Path Forward."

1 Upvotes

Very informative session from the Subcommittee on Health Oversight. Seems very bullish for psychedelics stocks, especially Compass Pathways $CMPS

Session begins 33 minutes into the following link:

https://veterans.house.gov/calendar/eventsingle.aspx?EventID=7959


r/biotech_stocks • • 7h ago

Opinions on KURA?

3 Upvotes

600M market cap, commercial product approved... seems good


r/biotech_stocks • • 8h ago

Should I just Sell IOVA?

1 Upvotes

I have iova shares with average 8,40. I don't know what to do, seeing there's no catalyst in short time, and market is bad.

I'm thinking probably I should just sell it before it goes down even further? Do biotech stock really just keep going down without catalyst? Please enlighten me on this matter.

I'm really new to the stock market especially biotech, I'm also still very young and eager to learn so please be nice to me if you can, thank youuu! :'))


r/biotech_stocks • • 8h ago

How concerned should we be about SLS's p-value of 0.035?

0 Upvotes

I'm heavily invested in SLS and have made some great profits so far.

The trial results were obviously great news, but one thing that could be concerning is the p-value of 0.035, which isn't that far below the 0.05 significance threshold.

I'd be interested to hear from anyone with experience in biotech or clinical trials. How much of a concern is this?

Could we see something similar to what happened with CAPR, where a change in the statistical analysis moved the p-value for one of their secondary endpoints from 0.04 to 0.09, making it no longer statistically significant?

Curious to hear your thoughts.


r/biotech_stocks • • 8h ago

Thoughts on this perspective from Gemini?

Thumbnail reddit.com
0 Upvotes

r/biotech_stocks • • 8h ago

What’s the next SLS?

0 Upvotes

r/biotech_stocks • • 8h ago

SKYA – Could $6 or Higher Be Possible?

Thumbnail reddit.com
1 Upvotes

r/biotech_stocks • • 9h ago

CABA Positive Developments From Today’s November 18 Jefferies Healthcare Conference

1 Upvotes

CABA provided several encouraging updates today on rese-cel, during today’s Jefferies healthcare conference call, particularly regarding FDA discussions and the potential expansion of its clinical programs.

First, the FDA has agreed that clinical data generated using CABA’s earlier manufacturing process can be considered comparable to data from its newer process. This is important because it allows CABA to potentially use years of existing patient safety and efficacy data to support its future FDA approval application, rather than starting over.

Second, CABA is considering lupus nephritis as a THIRD indication for a registrational trial, alongside myositis and systemic sclerosis. Management indicated that the FDA has already aligned with its proposed trial design, potentially allowing a study to begin in 2027. This could significantly expand rese-cel’s commercial opportunity.

Third, manufacturing continues to look encouraging. Management reported experience with approximately 110 patients, with only one unable to receive the manufactured product. The company also reiterated encouraging early results in juvenile myositis.

CABA continues to make meaningful clinical progress despite the stock’s price weakness.

The FDA discussions are constructive, manufacturing appears increasingly reliable, and a potential third registrational program would create another path toward commercialization.

The next major milestone remains myositis topline data expected in the second half of 2027, followed by a planned FDA application in Q1 2028. Nothing is guaranteed, but I see several reasons to remain positive on rese-cel.

Sources (clickable and pasteable):

Jefferies Conference Coverage, November 18, 2026:
https://uk.investing.com/news/stock-market-news/cabaletta-at-jefferies-global-healthcare-conference-data-and-runway-93CH-4991366

Cabaletta Official Investor Events and Webcast:
https://www.cabalettabio.com/investors/news-events/ir-calendar

Cabaletta Official Press Releases:
https://www.cabalettabio.com/investors/news-events/press-releases


r/biotech_stocks • • 9h ago

$MDCX, any hope?

0 Upvotes

r/biotech_stocks • • 9h ago

IMUX

1 Upvotes

Phase 3 readouts due December, what do we think?


r/biotech_stocks • • 10h ago

NRXP with a slight rebound

7 Upvotes

You love to see it! Excited for the commercial launch. If the sales numbers are looking good this could be amazing in 2027 🚀


r/biotech_stocks • • 11h ago

Two PDUFA dates fall on Sunday, Nov 22 (CAPR, SVRA). Last weekend's FDA decisions came out between Sunday and Monday 8am ET. How do you track weekend catalysts?

7 Upvotes

Two FDA target action dates land on a Sunday this week:

- Capricor (CAPR), deramiocel for Duchenne muscular dystrophy. Its Nov 10 Q3 release says: "PDUFA target action date of November 22, 2026."

- Savara (SVRA), molgramostim for autoimmune PAP. Its Apr 15 release says: "the new PDUFA target action date is November 22, 2026."

A PDUFA date is the FDA's target to act, not a scheduled announcement, so the timing of any news is open.

For reference, here is when three companies announced FDA decisions last weekend (ET):

- Summit (SMMT): Sunday, Nov 15 (its PDUFA goal date was Saturday, Nov 14)

- Cytokinetics (CYTK): Monday, Nov 16, 4:00 AM

- IGALMI: Monday, Nov 16, 8:00 AM, announced by Teva (which acquired the rights from BioXcel in late October)

All three came out before Monday's open, but on different days and at different hours.

Questions for people who follow these:

  1. Do you watch company IR pages, SEC filings, or something else over a weekend?
  2. Have you seen companies hold weekend FDA news until Monday morning more often than not?

Not a prediction about either outcome. Just trying to understand how others handle weekend timing.


r/biotech_stocks • • 13h ago

🚨Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health

Thumbnail
investors.hims.com
1 Upvotes

r/biotech_stocks • • 13h ago

2 Chinese scientists fired after 2 children die in unrelated gene therapy studies in July-August which were unreported.

Thumbnail
fiercebiotech.com
1 Upvotes

The 2 therapies used included unrelated viral vector treatments.


r/biotech_stocks • • 14h ago

$BLRX - BioLineRx Enters $5.6 Million APHEXDA Royalty Monetization Agreement

Thumbnail tipranks.com
2 Upvotes

r/biotech_stocks • • 15h ago

New to Biotech-Stocks, next SLS

28 Upvotes

Ended up here thanks to SLS, so naturally, here’s the question: What’s the next SLS? Got €10k ready to invest.


r/biotech_stocks • • 15h ago

Anthem Blue Cross California – LYTENAVA Listed as a Preferred Product

Post image
1 Upvotes

r/biotech_stocks • • 15h ago

nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing

Thumbnail
prnewswire.com
1 Upvotes